Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
Date:7/20/2009

on as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

                           IDENIX PHARMACEUTICALS, INC.

                  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                      (IN THOUSANDS, EXCEPT PER SHARE DATA)

                                    (UNAUDITED)

                                  Three Months Ended      Six Months Ended
                                       June 30,               June 30,
                                  ------------------      ----------------
                                   2009        2008       2009        2008
    Revenues:                      ----        ----       ----        ----
      Collaboration revenue -
       related party             $2,182      $1,433     $6,098      $3,478
      Other revenue                 267         159        362         157
                                    ---         ---        ---         ---
        Total revenues            2,449       1,592      6,460       3,635
    Operating expenses(1):
      Cost of revenues              492         415        954         810
      Research and
       development               11,400      14,136     22,250      29,004
      General and
       administrative             5,357       6,651     11,373      14,972
      Restructuring charges       1,506          37      1,506         297
                                  -----          --      -----         ---
        Total operating
         expenses                18,755      21,239     36,083      45,083
                                 ------      ------     ------      ------
  
'/>"/>
SOURCE  Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 

Related biology technology :

1. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
2. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
3. Idenix Pharmaceuticals Reports First Quarter Financial Results
4. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
5. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
6. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
8. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
9. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
10. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... NEW YORK , May 22, 2013 /PRNewswire/ ... pioneering the development of disease modifying therapeutics for ... today the completion of its Series B financing, ... shares and warrants that would represent approximately $2.8M ... investors and new investors supported the raise. ...
(Date:5/22/2013)... N.H. , May 22, 2013  Superior ... the Year 2013" by Business NH Magazine.  For ... Granite State organizations that distinguish themselves with extraordinary ... very proud to receive this honor," said ... Controls.  "As with any recognition, this award is ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Genedata, ... industrial biotechnology, drug discovery, and life science research, ... Selector ™ as its bioinformatics platform for ... organisms. Genedata will provide AB Enzymes, one of ... a hosted solution of Genedata Selector accompanied by ...
(Date:5/22/2013)... 22, 2013 AudioNotch ... for tinnitus treatment. AudioNotch is pleased to announce ... clinic locations in both British Columbia and Alberta, ... and hearing services. AudioNotch's tinnitus treatment program is ... entering a Destination Hearing clinic, patients have the ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2
... on QuatRx clinical development programs, including review of positive results ... ... ANN ARBOR, Mich., Jan. 4 QuatRx Pharmaceuticals Company,today announced that ... presenter at the 26th Annual JP Morgan Healthcare,Conference on Tuesday, January ...
... the Company has been invited and has accepted to ... January 7-10, 2008 at,the Westin St. Francis Hotel in ... Chief Executive Officer will provide an,overview of the Company ... About JPMorgan 26th Annual Healthcare Conference, JPMorgan,s premier ...
... safety and efficacy in treatment of multi-drug ... resistant infections ... or the "Company"), a biopharmaceutical company focused on the,development of novel ... the first patients in two,separate Phase 2 clinical trials. The studies ...
Cached Biology Technology:QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 3
(Date:5/21/2013)... ANN ARBORThe new University of Michigan Water Center ... to support Great Lakes restoration and protection efforts. ... will support diverse projects, including efforts to track ... effectiveness of techniques to control non-native weedy plant ... and monitor fish responses to restoration activities. , ...
(Date:5/21/2013)... scientists have developed many devices that can reopen clogged ... effective, each of these treatments has drawbacks, including the ... MIT analyzes the potential usefulness of a new treatment ... stents, but may pose fewer risks. With this new ... only a brief period, during which it releases a ...
(Date:5/20/2013)... are also commonly resistant to antimicrobial substances made ... in mBio , the online open-access journal ... colistin and host antimicrobials LL-37 and lysozyme, which ... mean that patients with life-threatening multi-drug resistant infections ... Colistin is a last-line drug for treating several ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... Montral, June 23, 2009 On June 18, the ... $9.16 million for the creation of a national technology ... platform, headed by Dr. Benoit Coulombe from the Institut ... provide Canadian researchers with new state-of-the-art equipment in proteomics, ...
... 2009) University of Minnesota Medical School researchers have discovered an ... to treat those infected by a parasitic flatworm. ... The Schistosomasis parasite infects about 200 million people in ... where people become infected simply by bathing, drinking, or cooking water ...
... whips up more powerful and frequent hurricanes and storms, the ... breed and recover from damage. That,s one of the ... corals in the wake of large climate-driven bleaching and storm ... the regrowth of young corals drops sharply in ...
Cached Biology News:A Canada-wide technology platform for mapping the human interactome 2U of M study finds new insight on therapy for a devastating parasitic disease 2Coral face 'a stormy future' 2
... The IEC Centra CL3 series ... in typical research and clinical applications ... broad accessory package includes quick connect ... An advanced yet intuitive interface allows ...
PP2B-Abeta (C-20)...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... H2OBIT™ is a fully licensed, high throughput, water ... of up to 24 microplates. This equates to ... A robotic arm rapidly transfers a ... in temperature ramping times that are considerably faster ...
Biology Products: